Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
RNA

Price
72.86
Stock movement down
-0.04 (-0.06%)
Company name
Atrium Therapeutics, Inc. Common Stock
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
10.51B
Ent value
10.44B
Price/Sales
1038.84
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return (CAGR)
73.22%
3 year return (CAGR)
-
5 year return (CAGR)
-
10 year return (CAGR)
-
Last updated: 2025-12-04

DIVIDENDS

RNA does not pay dividends or no data was received

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales1038.84
Price to Book-
EV to Sales1032.16

FINANCIALS

Per share

Per share data
Current share count146.91M
EPS (TTM)-4.97
FCF per share (TTM)-4.84

Income statement

Income statement data
Revenue (TTM)18.75M
Gross profit (TTM)-120.87M
Operating income (TTM)-745.94M
Net income (TTM)-684.63M
EPS (TTM)-4.97
EPS (1y forward)-4.03

Margins

Margins data
Gross margin (TTM)-644.45%
Operating margin (TTM)-3977.30%
Profit margin (TTM)-3650.39%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash382.52M
Net receivables12.44M
Total current assets1.80B
Goodwill0.00
Intangible assets0.00
Property, plant and equipment8.35M
Total assets1.96B
Accounts payable12.40M
Short/Current long term debt94.56M
Total current liabilities195.45M
Total liabilities269.45M
Shareholder's equity1.69B
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-650.44M
Capital expenditures (TTM)16.49M
Free cash flow (TTM)-666.93M
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity-40.54%
Return on Assets-34.96%
Return on Invested Capital-40.45%
Cash Return on Invested Capital-39.40%

STOCK INFORMATION

Stock chart

Stock price data
Open71.54
Daily high71.69
Daily low71.42
Daily Volume1.34M
All-time high72.93
1y analyst estimate74.64
Beta0.93
EPS (TTM)-4.97
Dividend per share0.00
Ex-div date-
Next earnings date3 Mar 2026

Downside potential

Downside potential data
RNAS&P500
Current price drop from All-time high-0.10%-1.82%
Highest price drop-54.13%-56.47%
Date of highest drop8 Apr 20259 Mar 2009
Avg drop from high-27.17%-10.84%
Avg time to new high22 days12 days
Max time to new high237 days1805 days
COMPANY DETAILS
RNA (Atrium Therapeutics, Inc. Common Stock) company logo
Marketcap
10.51B
Marketcap category
Large-cap
Description
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivery of RNA therapeutics to the heart to transform the care for people living with cardiomyopathies. The company offers ATR 1072, is a potentially disease-modifying treatment for PRKAG2 syndrome; ATR 1086 for phospholamban (PLN) cardiomyopathy. The company also provides cardiac disease pipeline, includes PRKAG2 syndrome, PLN cardiomyopathy. The company was formerly known as Bryce Therapeutics, Inc. Atrium Therapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. Atrium Therapeutics, Inc. operates as a subsidiary of Avidity Biosciences, Inc.
Employees
511
Website
https://www.aviditybiosciences.com
Investor relations
-
SEC filings
RNA SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesAbout usFeatured ArticlesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2026 Skyfall Technology OÜ All Rights Reserved